An unconventional law firm partnership announced Monday shows how attorneys are seeking the benefits of a merger without ...

Corporate programs designed to boost diversity, equity, and inclusion are poised to encounter further legal threats this year ...

Disability discrimination claims from neurodiverse employees with conditions like autism are growing along with increased ...

A list of pharmaceutical representatives at the table when the Biden administration negotiated Medicare drug prices reveals ...

In a social media fracas over H-1B visas around the holidays, Elon Musk cast himself as a foil to fellow MAGA supporters of ...

Companies are tailoring their noncompetes and seeking alternatives in response to state-level restrictions, even as the fate ...

Two disputes concerning blank-check companies linked to President-elect Donald Trump’s Truth Social platform and, separately, ...

Stinson’s Renée Steinle says potential audits, workplace raids, and elimination of immigration programs will pose risks to ...

The Department of Health and Human Services’ first major revamp in two decades to its cybersecurity rules would require the ...

ATOZ Tax Advisers’ Andreas Medler and Marie Bentley explain how DAC9 eases reporting burdens, but say some practical ...

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, for about $14.6 billion, the company said.

A Simpson Thacher & Bartlett partner is leaving after less than three months at the firm to join his mentor Dave Grubman, who is now co-leading Sidley Austin’s global mergers and acquisitions practice ...